Whole genome sequencing gives you the most complete picture of your genetic makeup that medicine can currently produce. But a picture is only useful if someone can read it accurately. And reading it accurately — particularly when two variants appear in the same gene — is far more complicated than most patients, and many physicians, realize.

Genes Come in Pairs

Every gene in your body exists in two copies: one inherited from your mother, one from your father. These two copies are called alleles, and they sit on paired chromosomes — one in each pair carrying the maternal version, the other carrying the paternal version.

When a whole genome sequencing report identifies a genetic variant, it is telling you that one or both of your alleles differ from the reference sequence at a particular location. A single variant in one allele is straightforward to interpret. Two variants in the same gene is where the complexity begins.

The Phase Problem: Cis vs. Trans

When two variants are identified within the same gene, the critical question is: do they sit on the same chromosome, or on opposite chromosomes?

• Cis orientation — both variants are on the same allele (the same chromosome). They travel together, are expressed together, and their combined effect is limited to one copy of the gene. The other allele, carrying neither variant, functions normally.

• Trans orientation — the variants are split across the two alleles. Each chromosome carries one variant. Both copies of the gene are affected, each in a different way.

This distinction is called phase, and it fundamentally determines the clinical outcome. The same two variants, in the same gene, produce entirely different physiologic effects depending on whether they are in cis or trans.

Standard whole genome sequencing — even at the highest coverage — cannot reliably determine phase. The sequencing reads are too short to span both variant positions simultaneously in most cases, so the report tells you what variants exist but not which chromosome each one is on. That determination requires additional testing, computational inference, or clinical reasoning based on population genetics data.

A Real-World Example: CYP2C19

The CYP2C19 gene encodes a liver enzyme responsible for metabolizing a wide range of clinically important medications — including clopidogrel (Plavix), several antidepressants, proton pump inhibitors, and certain antifungals.

Variants in CYP2C19 are among the most well-studied in all of pharmacogenomics. Two of the most common are:

• CYP2C19*2 — a loss-of-function variant that reduces or eliminates enzyme activity
• CYP2C19*17 — a gain-of-function variant that increases enzyme activity

Now suppose a patient's whole genome sequencing report identifies both of these variants. What does that mean clinically?

If the variants are in trans — *2 on one chromosome, *17 on the other — the patient has one allele that produces reduced enzyme activity and one that produces increased activity. These effects partially offset each other. Depending on the specific combination, the patient may function as a normal metabolizer or an intermediate metabolizer. The clinical implication is relatively moderate.

If the variants are in cis — both *2 and *17 on the same chromosome — the picture changes entirely. The chromosome carrying both variants has its activity profile altered in a complex way that is not simply the sum of the two effects. The other chromosome, carrying neither variant, functions normally. The patient's overall metabolizer status is now driven primarily by that normal allele, and the clinical interpretation shifts accordingly.

The same two variants. The same gene. Opposite chromosomal arrangements. Meaningfully different clinical implications for every medication that runs through the CYP2C19 pathway.

For a detailed look at how CYP2C19 variant combinations are reported and interpreted in clinical practice, see the reference document below — an actual Sequencing.com result for Dr. Mike Vaughn (*HIPAA rights waived):

Download PDF

The Phenotype: Where Genetics Meets Physiology

The term phenotype refers to the observable, physiologic result of your genes actually functioning in your body. It is the downstream consequence of everything happening at the molecular level — enzyme activity, drug metabolism rates, protein structure, cellular signaling.

Two people can carry identical genotypes (the same variants, in the same gene) and still express different phenotypes if the phase of those variants differs. This is not a theoretical edge case. It is a routine feature of complex genetic interpretation that has direct consequences for prescribing decisions.

When a physician looks at a pharmacogenomic report and sees two variants flagged in CYP2C19, the question is not simply "what do these variants do?" The question is "what do these variants do together, on these specific chromosomes, in this specific patient?" That question requires a working knowledge of population haplotype data, an understanding of how inference algorithms handle phase uncertainty, and enough time to reason through the clinical implications for every drug in the patient's current and anticipated medication list.

Why Most Primary Care Physicians Cannot Do This

This is not a criticism of primary care physicians. It is an honest assessment of the structural conditions under which most of them practice.

A physician managing a panel of 2,000 to 3,000 patients operates under relentless time pressure. The average primary care appointment in a traditional insurance-based practice runs 15 to 20 minutes. In that window, the physician must address the presenting complaint, review medications, order or follow up on labs, document the encounter, and handle any acute concerns that arise. There is no time remaining to open a 40-page whole genome sequencing report and work through the phase implications of two CYP2C19 variants.

Beyond time, there is the matter of training. Genetics and genomics received limited attention in most medical school curricula until recently, and continuing medical education in pharmacogenomics has been inconsistent. A physician who graduated even ten years ago may have had minimal formal exposure to the concepts of allelic phase, haplotype inference, or the clinical significance of gain-of-function variants. This is not a failure of the individual physician — it is a gap in how the profession has historically been trained.

The result is a predictable pattern: the WGS report arrives, the physician acknowledges it, and the information is filed without being meaningfully integrated into the patient's care. Not because the physician does not care, but because the system they practice in does not give them the tools, the time, or the training to do otherwise.

Genetics Touches Almost Every Aspect of Preventive Care

The implications of whole genome sequencing extend far beyond which statin to prescribe. A patient's genetic profile is relevant to:

• Cardiovascular risk — variants affecting lipid metabolism, clotting factor activity, and blood pressure regulation
• Cancer screening — variants in BRCA1/2, Lynch syndrome genes, and other hereditary cancer pathways that change when and how aggressively screening should begin
• Mental health treatment — CYP2D6 and CYP2C19 variants that determine whether an antidepressant will be effective or cause intolerable side effects
• Metabolic health — variants affecting insulin sensitivity, vitamin D metabolism, and inflammatory pathways
• Medication safety across the board — from anticoagulants to antibiotics to anesthesia agents, dozens of commonly used drugs have pharmacogenomic interactions that a complete genetic profile can illuminate

Integrating this information into a patient's care is not a one-time event. It is an ongoing clinical practice — one that requires revisiting the genetic data every time a new medication is considered, every time a new diagnosis is made, and every time the evidence base for a particular gene-drug interaction is updated.

That kind of longitudinal, genetics-informed care requires a physician who has the time to do it, the training to do it well, and a practice model that makes it structurally possible.

What Direct Primary Care Changes

At Enlightened Primary Care, our patient panel is capped at 299 members. That limit is not arbitrary — it is the number that allows us to practice medicine at the depth this kind of care requires.

When your whole genome sequencing results arrive, we review them. When two variants appear in the same gene, we work through the phase question — using population haplotype data, inference tools, and the published clinical literature — before drawing any conclusions about what those variants mean for your care. When a new medication is being considered, we check it against your complete pharmacogenomic profile, not just the variants that happen to appear on a targeted panel.

This is not a specialty service. It is what primary care looks like when the structural barriers of volume-based medicine are removed.

---

If you have had whole genome sequencing performed and are looking for a physician who can help you understand what the results actually mean for your health, we invite you to reach out. This is exactly the kind of medicine we are built to practice.